Laduviglusib

N/A

Report date: 2022/05/19 15:44:58
NME

Base Information

Drug NameLaduviglusib
Drug Alias NameCHIR-99021GTPL-8014CT-99021CHR-00921FX-03
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 beta inhibitorsWnt signalling pathway stimulantsGlycogen synthase kinase-3 alpha inhibitors
TargetsGlycogen synthase kinase-3 betaGlycogen synthase kinase-3 alpha
Therapy Area/IndicationsFetal Growth RetardationHearing Loss, Sensorineural
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFrequency Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesFrequency Therapeutics
Inactive CompaniesN/A
Active IndicationsFetal Growth RetardationHearing Loss, Sensorineural
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A